Literature DB >> 11053063

Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon.

A E Smyth1, A L Bell, I N Bruce, S McGrann, J A Allen.   

Abstract

OBJECTIVE: To determine circulating endothelin-1 levels (ET-1) in patients with primary or secondary associated Raynaud's phenomenon (RP) under resting conditions and in response to cold provocation.
METHODS: Patients were categorised as primary RP (18) or scleroderma associated RP (14). Finger blood flow was measured by venous occlusion plethysmography at finger temperatures of 32 degrees C and 24 degrees C. Vasospasm was detected as a finger systolic pressure of 0 mm Hg after standardised provocative cooling. Severity of vasospasm was assessed by the level of cooling required to provoke spasm. Plasma ET-1 levels were measured in antecubital blood withdrawn under baseline conditions (finger 32 degrees C) and at the point of vasospasm. Measurements were also made in 19 matched control subjects.
RESULTS: Finger blood flow was lower in patients with RP than in controls, with no difference between the two RP groups. Vasospasm occurred in all patients with RP but not in any control subjects and a grading system of severity was established. Baseline plasma ET-1 levels were similar in patients with RP and controls. Increases in ET-1 levels at the point of vasospasm in patients or corresponding timepoint in controls were also similar. There was no significant difference between the ET-1 levels in the two RP subgroups when the fingers were warm or when vasospasm was present.
CONCLUSIONS: These results do not support the hypothesis that ET-1 plays a part in the pathogenesis of RP. Objective testing is a useful adjunct to the clinical diagnosis of RP and allows assignment of a severity grade.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053063      PMCID: PMC1753024          DOI: 10.1136/ard.59.11.870

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

1.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

2.  Endothelin, vasoconstriction, and endothelial damage in Raynaud's phenomenon.

Authors:  C Cimminiello; M Milani; T Uberti; G Arpaia; S Perolini; G Bonfardeci
Journal:  Lancet       Date:  1991-01-12       Impact factor: 79.321

3.  Raised plasma endothelin-I concentration following cold pressor test.

Authors:  F Fyhrquist; O Saijonmaa; K Metsärinne; I Tikkanen; K Rosenlöf; T Tikkanen
Journal:  Biochem Biophys Res Commun       Date:  1990-05-31       Impact factor: 3.575

4.  Endothelin induces potent microvascular constriction.

Authors:  S D Brain; J R Tippins; T J Williams
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

5.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

6.  Diagnosis of Raynaud's phenomenon assisted by color charts.

Authors:  H R Maricq; M C Weinrich
Journal:  J Rheumatol       Date:  1988-03       Impact factor: 4.666

7.  A plethysmograph for the measurement of digital blood flow.

Authors:  S McGrann; S T Irwin; J A Allen
Journal:  J Med Eng Technol       Date:  1986 Nov-Dec

8.  Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon.

Authors:  C G Kallenberg; A A Wouda; T H The
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

Review 9.  The paracrine endothelin system: pathophysiology and implications in clinical medicine.

Authors:  B Hocher; C Thöne-Reineke; C Bauer; M Raschack; H H Neumayer
Journal:  Eur J Clin Chem Clin Biochem       Date:  1997-03

10.  Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon.

Authors:  M R Zamora; R F O'Brien; R B Rutherford; J V Weil
Journal:  Lancet       Date:  1990-11-10       Impact factor: 79.321

View more
  7 in total

Review 1.  Raynaud's phenomenon: epidemiology and risk factors.

Authors:  Liana Fraenkel
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 2.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

3.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

Review 4.  A vascular mechanistic approach to understanding Raynaud phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Nat Rev Rheumatol       Date:  2014-12-23       Impact factor: 20.543

5.  Current Treatment Options in Raynaud's Phenomenon.

Authors:  Sergio Generini; Angela Del Rosso; Alberto Pignone; Marco Matucci Cerinic
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-04

6.  Rapid free thiol rebound is a physiological response following cold-induced vasoconstriction in healthy humans, primary Raynaud and systemic sclerosis.

Authors:  Amaal Eman Abdulle; Anniek M van Roon; Andries J Smit; Andreas Pasch; Matijs van Meurs; Hendrika Bootsma; Stephan J L Bakker; Mohammad Y Said; Bernadette O Fernandez; Martin Feelisch; Harry van Goor; Douwe J Mulder
Journal:  Physiol Rep       Date:  2019-03

7.  Herbal Prescription, DSGOST, Prevents Cold-Induced RhoA Activation and Endothelin-1 Production in Endothelial Cells.

Authors:  Sung-Gook Cho; Ho Yeon Go; Jeong-Su Park; Ki-Yong Jung; Seung-Ho Sun; You-Kyung Choi; Yun-Kyung Song; Jong-Hyeong Park; Chan-Yong Jun; Seong Gyu Ko
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-15       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.